Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype

Epigenetics and Chromatin

Volumn 8, Issue 1, 2015, Pages

  Sánchez Vega, Francisco ^a   Gotea, Valer ^a   Margolin, Gennady ^a   Elnitski, Laura ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; CIMP; CpG island methylator phenotype; DNA methylation; ENCODE; Pan cancer; TCGA

Indexed keywords

HISTONE METHYLTRANSFERASE;

ARTICLE; CANCER CELL LINE; CANCER RECURRENCE; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL FEATURE; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; DNA REPAIR; EPIGENETICS; EPITHELIUM TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE LOCUS; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION; STRATIFICATION; TISSUE SPECIFICITY; TUMOR DIFFERENTIATION;

EID: 84929155489     PISSN: None     EISSN: 17568935     Source Type: Journal    
DOI: 10.1186/s13072-015-0007-7     Document Type: Article

References (62)

1. Robertson KD, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet. 2000;1:11-9.
2. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(Suppl):245-54.
3. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057-68.
4. Baylin SB. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687-92.
5. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726-34.
6. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-9.
7. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002;196:1-7.
8. Issa J-PJ. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007;13:1634-7.
9. Esteller M. Cancer epigenetics for the 21st century: what's next? Genes Cancer. 2011;2:604-6.
10. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457-63.
11. Hughes LAE, Melotte V, de Schrijver J, de Maat M, Smit VTHBM, Bovée JVMG, et al. The CpG island methylator phenotype: what's in a name? Cancer Res. 2013;73:5858-68.
12. Issa J-P. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988-93.
13. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa J-PJ. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci. 1999;96:8681-6.
14. Hughes LAE, Khalid-de Bakker CAJ, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, et al. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 1825;2012:77-85.
15. Arain MA, Sawhney M, Sheikh S, Anway R, Thyagarajan B, Bond JH, et al. CIMP status of interval colon cancers: another piece to the puzzle. Am J Gastroenterol. 2010;105:1189-95.
16. Grady WM. CIMP and colon cancer gets more complicated. Gut. 2007;56:1498-500.
17. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int. 2011;2011:902674.
18. Weisenberger DJ. Characterizing DNA, methylation alterations from The Cancer Genome Atlas. J Clin Invest. 2014;124:17-23.
19. Witte T, Plass C, Gerhauser C. Pan-cancer patterns of DNA methylation. Genome Med. 2014;6:66.
20. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153:38-55.
21. Kim JH, Karnovsky A, Mahavisno V, Weymouth T, Pande M, Dolinoy DC, et al. LRpath analysis reveals common pathways dysregulated via DNA methylation across cancer types. BMC Genomics. 2012;13:526.
22. Sproul D, Kitchen RR, Nestor CE, Dixon JM, Sims AH, Harrison DJ, et al. Tissue of origin determines cancer-associated CpG island promoter hypermethylation patterns. Genome Biol. 2012;13:R84.
23. Kalari S, Pfeifer GP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet. 2010;70:277-308.
24. Research TCGA. Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-7.
25. Kolbe DL, DeLoia JA, Porter-Gill P, Strange M, Petrykowska HM, Guirguis A, et al. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One. 2012;7:e32941.
26. Research TCGA. Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
27. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127-33.
28. Sánchez-Vega F, Gotea V, Petrykowska HM, Margolin G, Krivak TC, DeLoia JA, et al. Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. Epigenetics. 2013;8:1355-72.
29. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet. 2011;43:768-75.
30. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest. 2010;120:533-44.
31. Messner S, Hottiger MO. Histone ADP-ribosylation in DNA repair, replication and transcription. Trends Cell Biol. 2011;21:534-42.
32. Kato J, Zhu J, Liu C, Stylianou M, Hoffmann V, Lizak MJ, et al. ADP-ribosylarginine hydrolase regulates cell proliferation and tumorigenesis. Cancer Res. 2011;71:5327-35.
33. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One. 2013;8:e55119.
34. Butler JS, Dent SYR. Chromatin "resetting" during transcription elongation: a central role for methylated H3K36. Nat Struct Mol Biol. 2012;19:863-4.
35. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283-96.
36. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291-310.
37. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787-93.
38. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006;8:582-8.
39. Serra RW, Fang M, Park SM, Hutchinson L, Green MR. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife. 2014;3:e02313.
40. De Vogel S, Weijenberg MP, Herman JG, Wouters KAD, de Goeij AFPM, van den Brandt PA, et al. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events. Ann Oncol. 2009;20:1216-22.
41. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315-22.
42. Research TCGA. Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
43. La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010;116:4696-702.
44. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847-54.
45. Soreide K. High-fidelity of five quasimonomorphic mononucleotide repeats to high-frequency microsatellite instability distribution in early-stage adenocarcinoma of the colon. Anticancer Res. 2011;31:967-71.
46. Nakayama K, Nakayama N, Ishikawa M, Miyazaki K. Endometrial serous carcinoma: its molecular characteristics and histology-specific treatment strategies. Cancers (Basel). 2012;4:799-807.
47. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LGT, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med. 2011;3:75ra25.
48. Faravelli F. NSD1 mutations in Sotos syndrome. Am J Med Genet C Semin Med Genet. 2005;137C:24-31.
49. NSD1 mutations in Sotos syndrome alter the DNA methylation landscape of genes involved in somatic growth and neuronal transmission. [http://www.ashg.org/2012meeting/abstracts/fulltext/f120122152.htm]
50. A specific DNA methylation signature associated with NSD1+/-mutations in Sotos syndrome reveals a significant genome-wide loss of DNA methylation (DNAm) targeting CGs in regulatory regions of key developmental genes. [ http://www.ashg.org/2013meeting/abstracts/fulltext/f130121963.htm ].
51. Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol. 2012;13:115-26.
52. Agger K, Cloos PAC, Christensen J, Pasini D, Rose S, Rappsilber J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007;449:731-4.
53. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39:232-6.
54. Hou J, Wu J, Dombkowski A, Zhang K, Holowatyj A, Boerner JL, et al. Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer. Am J Transl Res. 2012;4:247-56.
55. Rasmussen PB, Staller P. The KDM5 family of histone demethylases as targets in oncology drug discovery. Epigenomics. 2014;6:277-86.
56. Stefansson OA, Moran S, Gomez A, Sayols S, Arribas-Jorba C, Sandoval J, et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol Oncol. 2014;9:555-68.
57. Conway K, Edmiston SN, May R, Kuan P, Chu H, Bryant C, et al. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res. 2014;16:450.
58. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics. 2013;29:189-96.
59. Marabita F, Almgren M, Lindholm ME, Ruhrmann S, Fagerström-Billai F, Jagodic M, et al. An evaluation of analysis pipelines for DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Epigenetics. 2013;8:333-46.
60. Cline MS, Craft B, Swatloski T, Goldman M, Ma S, Haussler D, et al. Exploring TCGA pan-cancer data at the UCSC Cancer Genomics Browser. Sci Rep. 2013;3:2652.
61. Research TCGA. Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.
62. Hothorn, Torsten and Zeileis, Achim, (2014), partykit: A Modular Toolkit for Recursive Partytioning in R, Working Papers, Faculty of Economics and Statistics, University of Innsbruck, http://EconPapers.repec.org/RePEc:inn:wpaper:2014-10.